The HER2/HER3 heterodimer, stabilized by heregulin (HRG), has been identified as a strong oncogenic unit in breast cancer [5,8] and is associated with reduced relapse-free and decreased overall survival [9]. Here, ERBB2 is linked to breast carcinoma.